ONCOFID-P-B (Paclitaxel-Hyaluronic Acid) In The Intravesical Therapy Of Patients With Non-Muscle Invasive Cancer Of The Bladder. A Phase II Marker Lesion Study.

Trial Profile

ONCOFID-P-B (Paclitaxel-Hyaluronic Acid) In The Intravesical Therapy Of Patients With Non-Muscle Invasive Cancer Of The Bladder. A Phase II Marker Lesion Study.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2018

At a glance

  • Drugs Paclitaxel-hyaluronic acid conjugate (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Sponsors Fidia Farmaceutici
  • Most Recent Events

    • 18 Mar 2018 According to a Fidia Farmaceutici media release, positive results were presented at the Italian Pharmaceutical R&D Excellence at the 33rd Congress of the European Association of Urology.
    • 18 Mar 2018 Results presented in a Fidia Farmaceutici media release.
    • 22 Oct 2016 This trial has been completed in Germany (end date: 4 Oct 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top